



PUBLIC NOTICE

National Formulary of India (NFI) 2026

This is to inform all stakeholders that the **National Formulary of India (NFI) 2026** is an authoritative reference document intended to promote the rational use of medicines in India. It provides evidence-based information and guidance to healthcare professionals on the prescribing, dispensing, and administration of medicines to support informed clinical decision-making and appropriate pharmacotherapy. The National Formulary of India is one of the necessary books as per Schedule N of The Drugs and Cosmetics Act, 1940 and Rules thereunder, as amended from time to time.

NFI is a guidance document and is neither legally binding nor a substitute for applicable statutory provisions and regulatory requirements.

The inclusion of medicine monographs in the NFI 2026 is guided by one or more of the following criteria:

1. Drugs included in the National List of Essential Medicines (NLEM), India
2. Drugs used under National Health Programmes (NHPs)
3. Drugs approved by the Central Drugs Standard Control Organisation (CDSCO)
4. Drugs for which standards are specified in the Indian Pharmacopoeia (IP)
5. Drugs recommended by the relevant panel of Subject Experts based on the following
 - i. Drugs having Clinical relevance and usage during emergencies and health crises
 - ii. Drugs approved by the State Licensing Authority under Chapter IV of the Drugs and Cosmetics Act, 1940, as applicable.
 - iii. Drugs included under Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) to promote access to quality generic medicines at affordable prices.

The medicine monograph and its formulation's usual strengths, as specified in individual monographs, are based on medical and pharmaceutical literature, including information from applicable CDSCO approvals, NLEM, drugs used in National Health Programmes, and inputs from relevant Subject Experts, as applicable. The inclusion of particular formulation strengths in an NFI monograph does not, by itself, imply that other strengths of the same medicine cannot be prescribed.

Healthcare professionals are expected to exercise their professional judgement and clinical expertise when prescribing medicines to their patients. Applicable statutory provisions and regulatory requirements shall prevail in the event of any inconsistency with the contents of the Formulary.

The NFI is a dynamic document that is periodically reviewed and updated through amendments, taking into consideration clinical inputs, emerging evidence and relevant recommendations to ensure its continued clinical relevance.

The stakeholders are encouraged to provide their comments, suggestions, and clinical inputs for consideration in future revisions of the NFI. Feedback may be communicated to the Indian Pharmacopoeia Commission (IPC) at lab.ipc@gov.in.

(Dr. K.K. Singh)

Library and Information Officer

INDIAN PHARMACOPOEIA
(IP)

Official Book of Drug Standards
in India

IP REFERENCE SUBSTANCES
(IPRS) AND IMPURITIES

Official Physical Standards for
Assessing the Quality of Drugs

NATIONAL FORMULARY OF INDIA
(NFI)

Reference Book to Promote Rational
Use of Generic Medicines

PHARMACOVIGILANCE PROGRAMME OF INDIA
(PvPI)



WHO Collaborating Centre for Pharmacovigilance
in Public Health Programmes and Regulatory
Services